RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
China Resources Pharmaceutical Group Stock

China Resources Pharmaceutical Group Liabilities 2024

China Resources Pharmaceutical Group Liabilities

200.81 B CNY

Ticker

3320.HK

ISIN

HK0000311099

WKN

A2ATTU

In 2024, China Resources Pharmaceutical Group's total liabilities amounted to 200.81 B CNY, a 16.77% difference from the 171.98 B CNY total liabilities in the previous year.

China Resources Pharmaceutical Group Aktienanalyse

What does China Resources Pharmaceutical Group do?

China Resources Pharmaceutical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing China Resources Pharmaceutical Group's Liabilities

China Resources Pharmaceutical Group's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating China Resources Pharmaceutical Group's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing China Resources Pharmaceutical Group's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

China Resources Pharmaceutical Group's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in China Resources Pharmaceutical Group’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about China Resources Pharmaceutical Group stock

What is the level of liabilities of China Resources Pharmaceutical Group this year?

China Resources Pharmaceutical Group has a debt balance of 200.81 B CNY this year.

What were the liabilities of China Resources Pharmaceutical Group compared to the previous year?

The liabilities of China Resources Pharmaceutical Group have increased by 16.77% increased compared to the previous year.

What are the consequences of high debt for investors of China Resources Pharmaceutical Group?

High liabilities can pose a risk for investors of China Resources Pharmaceutical Group, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in China Resources Pharmaceutical Group?

Low liabilities mean that China Resources Pharmaceutical Group has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of China Resources Pharmaceutical Group affect the company?

An increase in liabilities of China Resources Pharmaceutical Group can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of China Resources Pharmaceutical Group affect the company?

A decrease in the liabilities of China Resources Pharmaceutical Group can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of China Resources Pharmaceutical Group?

Some factors that can influence the liabilities of China Resources Pharmaceutical Group include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of China Resources Pharmaceutical Group so important for investors?

The liabilities of China Resources Pharmaceutical Group are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can China Resources Pharmaceutical Group take to modify the liabilities?

To change its liabilities, China Resources Pharmaceutical Group can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does China Resources Pharmaceutical Group pay?

Over the past 12 months, China Resources Pharmaceutical Group paid a dividend of 0.16 CNY . This corresponds to a dividend yield of about 3.63 %. For the coming 12 months, China Resources Pharmaceutical Group is expected to pay a dividend of 0.17 CNY.

What is the dividend yield of China Resources Pharmaceutical Group?

The current dividend yield of China Resources Pharmaceutical Group is 3.63 %.

When does China Resources Pharmaceutical Group pay dividends?

China Resources Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, July, October, October.

How secure is the dividend of China Resources Pharmaceutical Group?

China Resources Pharmaceutical Group paid dividends every year for the past 12 years.

What is the dividend of China Resources Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.17 CNY are expected. This corresponds to a dividend yield of 3.84 %.

In which sector is China Resources Pharmaceutical Group located?

China Resources Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von China Resources Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of China Resources Pharmaceutical Group from 10/30/2024 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did China Resources Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 10/30/2024.

What was the dividend of China Resources Pharmaceutical Group in the year 2023?

In the year 2023, China Resources Pharmaceutical Group distributed 0.15 CNY as dividends.

In which currency does China Resources Pharmaceutical Group pay out the dividend?

The dividends of China Resources Pharmaceutical Group are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von China Resources Pharmaceutical Group

Our stock analysis for China Resources Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of China Resources Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.